TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 7879931
Drug: Interpleural saline
Approvals — FDA: no, EMA: no, PMDA: no
Description: Interpleural saline and 1.5 mg intravenous morphine
Study: 7879931
Drug: Interpleural bupivacaine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Interpleural bupivacaine (30 ml 0.25%)
Study: 30657891
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of rosuvastatin with candesartan/HCT
Study: 19207601
Drug: Etravirine 800
Normalized name: Etravirine
DrugBank: Etravirine (DB06414)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Etravirine 800 mg bid (Study 1)
Study: 19207601
Drug: Etravirine 200
Normalized name: etravirine 200 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Etravirine 200 mg bid (Study 2)
Study: 17227264
Drug: Heparin (500
Approvals — FDA: no, EMA: no, PMDA: no
Description: Heparin (500 IU) in normal saline (HS)
Study: 10745070
Drug: Lunelle Monthly
Normalized name: Lunelle Monthly Contraceptive 5mg-25mg/0.5ml Suspension for Injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lunelle Monthly Contraceptive Injection (MPA/E(2)C)
Study: 9193192
Drug: Intravenous meta-chlorophenylpiperazine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous meta-chlorophenylpiperazine (mCPP) 0.1 mg/kg
Study: 8262115
Drug: Luteinizing hormone-releasing
Normalized name: (6-D-Tryptophan)luteinizing hormone-releasing hormone
Approvals — FDA: no, EMA: no, PMDA: no
Description: Luteinizing hormone-releasing hormone analogue depot preparation and flutamide
Study: 3543785
Drug: Balanced Saline
Approvals — FDA: no, EMA: no, PMDA: no
Description: Balanced Saline Solution (BSS)
Study: 22744718
Drug: Short- and
Normalized name: ALLERGENIC EXTRACT,RAGWEED,SHORT AND TALL
Approvals — FDA: no, EMA: no, PMDA: no
Description: Short- and long-term antibiotic treatments
Study: 18986066
Drug: Facial biological
Normalized name: beremagene geperpavec
DrugBank: Beremagene geperpavec (DB17831)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Facial biological motion recognition task
Study: 11488118
Drug: Standard polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard polyethylene glycol preparation
Study: 9232521
Drug: RheothRx injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: RheothRx injection (poloxamer 188) administered as an intravenous infusion at doses of 10, 30, and 45 mg/kg/h for 72 h, 60 mg/kg/h for 43.3 to 72 h, 60 and 90 mg/kg/h for 24 h
Study: 8121319
Drug: Buflomedil (600
Approvals — FDA: no, EMA: no, PMDA: no
Description: Buflomedil (600 mg per day for 21 days)
Study: 27267983
Drug: Multimodal educational
Normalized name: DIABETES PATIENT EDUCATION PACK
Approvals — FDA: no, EMA: no, PMDA: no
Description: Multimodal educational intervention consisting of two online modules, a face-to-face workshop for GP trainees, a face-to-face workshop for their supervisors, and case-based discussions in weekly meetings.
Study: 19644849
Drug: Golimumab 50
Normalized name: GOLIMUMAB 50MG/0.5ML INJ SYRINGE
Approvals — FDA: no, EMA: no, PMDA: no
Description: Golimumab 50 mg plus MTX
Study: 18383539
Drug: Golimumab 100
Normalized name: golimumab 100 MG/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: Golimumab 100 mg every 2 weeks plus MTX
Study: 12580985
Drug: High enalaprilat
Normalized name: Enalaprilat
DrugBank: Enalaprilat (DB09477)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: High enalaprilat concentration (above 50 ng ml(‐1), n = 17)
Study: 12580985
Drug: Low enalaprilat
Normalized name: Enalaprilat
DrugBank: Enalaprilat (DB09477)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Low enalaprilat concentration (below 10 ng ml(‐1), n = 18)
Study: 11966062
Drug: Single dose
Normalized name: Citrucel Single Dose Packets (Orange)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single dose of oral prednisolone (30 mg if age < 5 years; 60 mg if age > 5 years)
Study: 2983641
Drug: Oral estrogen
Normalized name: estrogens
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral estrogen treatment
Study: 29045621
Drug: Use of
Normalized name: OIL OF CAMPHOR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Use of proton pump inhibitors (PPIs)
Study: 29045621
Drug: Cumulative dosage
Normalized name: osage orange pollen extract
DrugBank: Maclura pomifera pollen (DB10988)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cumulative dosage of PPIs use (per microgram)
Study: 26175036
Drug: Fractional CO2
Normalized name: LIVER FRACTION
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fractional CO2 laser, NB‐UVB phototherapy, and 0.05% clobetasol propionate cream (Group A)
Study: 26175036
Drug: NB‐UVB phototherapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: NB‐UVB phototherapy and 0.05% clobetasol propionate cream (Group B)
Study: 21187536
Drug: Tranexamic acid
Normalized name: Tranexamic Acid
DrugBank: Tranexamic acid (DB00302)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Tranexamic acid (TA) - 10 mg per kg body weight, administered intravenously 10 minutes prior to incision
Study: 17982182
Drug: Prasugrel (60
Approvals — FDA: no, EMA: no, PMDA: no
Description: Prasugrel (60 mg loading dose and 10 mg daily maintenance dose)
Study: 17982182
Drug: Clopidogrel (300
Approvals — FDA: no, EMA: no, PMDA: no
Description: Clopidogrel (300 mg loading dose and 75 mg daily maintenance dose)
Study: 15476575
Drug: Calcium and
Normalized name: Calcium and Magnesium
DrugBank: Calcium carbonate (DB06724)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Calcium and cholecalciferol supplement (500 mg of elemental calcium and 400 IU cholecalciferol)
Study: 15476575
Drug: Neridronate (25
Approvals — FDA: no, EMA: no, PMDA: no
Description: Neridronate (25 mg intramuscularly every month) in addition to calcium and cholecalciferol supplement
Study: 11825486
Drug: recombinant human
Normalized name: Recombinant human TNF
DrugBank: Etanercept (DB00005)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: recombinant human growth hormone (rhGH) with total parenteral nutrition (TPN) for 7 days
Study: 11825486
Drug: total parenteral
Normalized name: TPN - total parenteral nutrition
Approvals — FDA: no, EMA: no, PMDA: no
Description: total parenteral nutrition (TPN) only for 7 days
Study: 8164328
Drug: Prostaglandin E1
Normalized name: Prostaglandin E1
DrugBank: Alprostadil (DB00770)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Prostaglandin E1 (PGE1) continuous infusion at a rate of 50 ng.kg‐1 x min‐1
Study: 8164328
Drug: Prostaglandin E1
Normalized name: Prostaglandin E1
DrugBank: Alprostadil (DB00770)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Prostaglandin E1 (PGE1) continuous infusion
Study: 2450113
Drug: Topical flunisolide
Normalized name: Flunisolide
DrugBank: Flunisolide acetate (DB14662)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Topical flunisolide (50 micrograms, each nostril, twice daily) for 1 week before antigen challenge
Study: 26857054
Drug: Internet-based cognitive-behavioral
Approvals — FDA: no, EMA: no, PMDA: no
Description: Internet-based cognitive-behavioral therapy for insomnia (CBT-I)
Study: 22774774
Drug: Combination therapy
Normalized name: REGN10933+REGN10987 combination therapy
DrugBank: Anti-SARS-CoV-2 REGN-COV2 (DB15691)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination therapy (dutasteride + tamsulosin)
Study: 17935974
Drug: Rituximab (Rit)
Normalized name: Rituximab
DrugBank: Rituximab (DB00073)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Rituximab (Rit) as a single agent
Study: 17935974
Drug: Rituximab (Rit)
Normalized name: Rituximab
DrugBank: Rituximab (DB00073)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Rituximab (Rit) in combination with chemotherapy
Study: 17935974
Drug: Addition of
Normalized name: OIL OF CAMPHOR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Addition of Rituximab to standard chemotherapy
Study: 14660152
Drug: Methamphetamine users
Approvals — FDA: no, EMA: no, PMDA: no
Description: Methamphetamine users entering treatment for methamphetamine dependence
Study: 15471834
Drug: L‐dopa therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: L‐dopa therapy response (normal scan)
Study: 15471834
Drug: L‐dopa therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: L‐dopa therapy response (abnormal scan)
Study: 2105052
Drug: Cyclic total
Normalized name: cyclic AMP
DrugBank: Cyclic adenosine monophosphate (DB02527)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cyclic total parenteral nutrition (15 h/d)
Study: 2105052
Drug: Continuous total
Normalized name: Zinc Oxide 7.25 g in 100 g / Titanium Dioxide 3.5 g in 100 g TOPICAL SPRAY [Kids SPF50 Plus Mineral Sunscreen Continuous Totally Tropical]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Continuous total parenteral nutrition (24 h/d)
Study: 31652407
Drug: Greek yogurt
Normalized name: Greek pitch
DrugBank: Rosin (DB11165)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Greek yogurt (GY) (20 g protein, 208 mg calcium/dose)
Study: 31652407
Drug: Placebo pudding
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo pudding (PP) (0 g protein, 0 g calcium/dose)
Study: 15476449
Drug: Diet plus
Normalized name: Glucomannan/Grapefruit Extract/Pyridoxine Oral Tablet [GRAPEFRUIT DIET PLUS]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Diet plus folic acid (5 mg/day) plus vitamin B12 (500 microg/day) for 1 month
Study: 9771301
Drug: Target-controlled alfentanil
Approvals — FDA: no, EMA: no, PMDA: no
Description: Target-controlled alfentanil infusion
Study: 3397586
Drug: 4‐methylpyrazole in
Approvals — FDA: no, EMA: no, PMDA: no
Description: 4‐methylpyrazole in hydrophilic ointment
Study: 3397586
Drug: Hydrophilic ointment
Normalized name: HYDROPHILIC OINTMENT
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hydrophilic ointment alone
Study: 31730565
Drug: CHO +
Normalized name: G-CSF (CHO cell derived)
Approvals — FDA: no, EMA: no, PMDA: no
Description: CHO + KME (573 mg·kg of a ketone monoester supplement)
Study: 31730565
Drug: CHO +
Normalized name: G-CSF (CHO cell derived)
Approvals — FDA: no, EMA: no, PMDA: no
Description: CHO + PLA (8% carbohydrate-electrolyte solution)
Study: 26132839
Drug: Chikungunya virus
Normalized name: Chikungunya virus Ab
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chikungunya virus (CHIKV) IgG antibodies testing
Study: 21666979
Drug: Placebo (inert
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (inert compound)
Study: 19709989
Drug: Negative credibility
Normalized name: GLYCERIN NEGATIVE CONTROL
Approvals — FDA: no, EMA: no, PMDA: no
Description: Negative credibility cues (adverts, pharmaceutical sponsorship, donation button)
Study: 15121070
Drug: No treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: No treatment (controls, 33 patients)
Study: 11476360
Drug: Lispro insulin
Normalized name: Lispro insulin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lispro insulin (LP)
Study: 9614617
Drug: Regular insulin
Normalized name: Regular insulin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Regular insulin (ACT)
Study: 31181017
Drug: Domperidone 0.25
Approvals — FDA: no, EMA: no, PMDA: no
Description: Domperidone 0.25 mg/kg with oral rehydration therapy (ORT)
Study: 31181017
Drug: Placebo with
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo with oral rehydration therapy (ORT)
Study: 24653477
Drug: Dignity therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dignity therapy plus standard care
Study: 15283941
Drug: Oral hormone
Normalized name: Parathyroid Hormone
DrugBank: Parathyroid hormone (DB05829)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral hormone replacement therapy (estradiol 2 mg/norethisterone acetate 1 mg-Kliogest)
Study: 8313746
Drug: Nylestriol 2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nylestriol 2 mg/2 weeks (Group A)
Study: 8313746
Drug: Nylestriol 1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nylestriol 1 mg/2 weeks (Group B)
Study: 29031768
Drug: Hyperbaric oxygenation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hyperbaric oxygenation therapy (100% oxygen in hyperbaric conditions)
Study: 11824669
Drug: Atorvastatin (40
Approvals — FDA: no, EMA: no, PMDA: no
Description: Atorvastatin (40 mg the evening before and 40 mg the morning of surgery)
Study: 9572206
Drug: Telephone calls
Normalized name: Mosco Corn & Callus Remover
Approvals — FDA: no, EMA: no, PMDA: no
Description: Telephone calls from registered nurses, one or two times weekly from 24 weeks' through 37 weeks' gestation
Study: 9572206
Drug: Telephone calls
Normalized name: Mosco Corn & Callus Remover
Approvals — FDA: no, EMA: no, PMDA: no
Description: Telephone calls from registered nurses, one or two times weekly from 24 weeks' through 37 weeks' gestation in low-income black women 19 years of age and older
Study: 27429228
Drug: Manuka honey
Normalized name: CVS Manuka Honey Wound Gel
Approvals — FDA: no, EMA: no, PMDA: no
Description: Manuka honey applied twice daily
Study: 21466650
Drug: Reduced-dose tacrolimus
Normalized name: Tacrolimus
DrugBank: Tacrolimus (DB00864)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Reduced-dose tacrolimus with mycophenolate mofetil
Study: 21466650
Drug: Standard-dose tacrolimus
Normalized name: Tacrolimus
DrugBank: Tacrolimus (DB00864)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Standard-dose tacrolimus
Study: 16701193
Drug: Epidural with
Normalized name: Primatene with ephedrine Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: Epidural with bupivacaine 0.1% and fentanyl 3mug/ml
Study: 16701193
Drug: Patient controlled
Normalized name: PATIENT CONTROLLED ANALGESIA VIAL
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patient controlled analgesia (PCA) with i.v. morphine
Study: 3083146
Drug: Short-term MF
Normalized name: hydrogen peroxide
DrugBank: Hydrogen peroxide (DB11091)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Short-term MF chemotherapy (mitomycin C, 0.04 mg/kg + 5-fluorouracil, 5.0 mg/kg X 6, IVr)
Study: 3083146
Drug: Long-term carmofur
Normalized name: benzethonium
DrugBank: Benzethonium (DB11125)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Long-term carmofur chemotherapy (Mifurol, 6-12 mg/kg/day over 12 weeks, PO)
Study: 3083146
Drug: Carmofur maintenance
Normalized name: Dental Resources Perio Maintenance Rinse
Approvals — FDA: no, EMA: no, PMDA: no
Description: Carmofur maintenance therapy
Study: 10579057
Drug: Eradication therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Eradication therapy consisting of metronidazole, bismuth subcitrate, and amoxicillin
Study: 8930145
Drug: Transdermal nicotine
Normalized name: nicotine Transdermal System
DrugBank: Nicotine (DB00184)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Transdermal nicotine patch (20 mg)
Study: 8930145
Drug: Transdermal nicotine
Normalized name: nicotine Transdermal System
DrugBank: Nicotine (DB00184)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Transdermal nicotine patch (30 mg)
Study: 8930145
Drug: Transdermal nicotine
Normalized name: nicotine Transdermal System
DrugBank: Nicotine (DB00184)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Transdermal nicotine patch (10 mg)
Study: 26771445
Drug: Febuxostat (80
Approvals — FDA: no, EMA: no, PMDA: no
Description: Febuxostat (80 mg QD)
Study: 26771445
Drug: Allopurinol (300
Approvals — FDA: no, EMA: no, PMDA: no
Description: Allopurinol (300 mg QD)
Study: 25376884
Drug: Whey-protein drink
Normalized name: whey protein hydrolysate
Approvals — FDA: no, EMA: no, PMDA: no
Description: Whey-protein drink (20 g daily plus 20 g after each PRT session) and vitamin D supplements (2000 IU/day)
Study: 25376884
Drug: No additional
Approvals — FDA: no, EMA: no, PMDA: no
Description: No additional powder and supplements (control group)
Study: 20545392
Drug: Codeine 30
Normalized name: codeine 30 MG
DrugBank: Codeine (DB00318)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Codeine 30 mg b.i.d. (0900 and 1300)
Study: 20545392
Drug: Codeine 30
Normalized name: codeine 30 MG
DrugBank: Codeine (DB00318)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Codeine 30 mg b.i.d.
Study: 9443524
Drug: Intensive treatment
Normalized name: Head & Shoulders Intensive Treatment
DrugBank: Selenium Sulfide (DB00971)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intensive treatment with risperidone
Study: 9443524
Drug: Intensive treatment
Normalized name: Head & Shoulders Intensive Treatment
DrugBank: Selenium Sulfide (DB00971)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intensive treatment without risperidone
Study: 9443524
Drug: Intensive treatment
Normalized name: Head & Shoulders Intensive Treatment
DrugBank: Selenium Sulfide (DB00971)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intensive treatment groups (both with and without risperidone)
Study: 8407738
Drug: Nedocromil sodium
Normalized name: Nedocromil Sodium
DrugBank: Nedocromil (DB00716)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Nedocromil sodium (4 mg, three times a day)
Study: 28203684
Drug: Crushed ticagrelor
Normalized name: Ticagrelor
DrugBank: Ticagrelor (DB08816)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Crushed ticagrelor tablets given orally
Study: 28203684
Drug: Crushed ticagrelor
Normalized name: Ticagrelor
DrugBank: Ticagrelor (DB08816)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Crushed ticagrelor tablets given sublingually
Study: 25440643
Drug: Control (1.8
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control (1.8 mL/h of normal saline)
Study: 19794940
Drug: MLG treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: MLG treatment
Study: 19794940
Drug: MLG+IVTA treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: MLG+IVTA treatment
Study: 19794940
Drug: IVTA treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: IVTA treatment
Study: 9089856
Drug: bupivacaine 1
Normalized name: bupivacaine 132 MG/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: bupivacaine 1 mg plus sufentanil 5 micrograms plus epinephrine 25 micrograms
Study: 9089856
Drug: bupivacaine 1
Normalized name: bupivacaine 132 MG/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: bupivacaine 1 mg plus sufentanil 5 micrograms
Study: 26976495
Drug: Caffeine (20
Approvals — FDA: no, EMA: no, PMDA: no
Description: Caffeine (20 mg/kg loading dose followed by 5 mg/kg daily maintenance until the 10th day of life)
Study: 25029955
Drug: Dulaglutide 0.25
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dulaglutide 0.25 mg
Study: 20809193
Drug: Music therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Music therapy for noisiform tinnitus
Study: 9552064
Drug: Granulocyte colony-stimulating
Normalized name: Granulocyte colony-stimulating factor lenograstim
DrugBank: Lenograstim (DB13144)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Granulocyte colony-stimulating factor (G-CSF) 16 microg/kg
Study: 9552064
Drug: High-dose cyclophosphamide
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose cyclophosphamide (HDCTX) 6 g/m2 plus G-CSF 5 microg/kg
Study: 7939138
Drug: Methotrexate (MTX)
Normalized name: Methotrexate
DrugBank: Methotrexate (DB00563)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Methotrexate (MTX) at an initial dose of 15 mg/week
Study: 7939138
Drug: Methotrexate (MTX)
Normalized name: Methotrexate
DrugBank: Methotrexate (DB00563)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Methotrexate (MTX) at an initial dose of 25 mg/week
Study: 3373405
Drug: Indomethacin (0.1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Indomethacin (0.1 mg/kg) administered intravenously every 24 hours for a total of three doses
Study: 3373405
Drug: Placebo (saline
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (saline solution) administered intravenously every 24 hours for a total of three doses
Study: 3373405
Drug: Saline solution
Normalized name: Unisol 4 Saline Solution
DrugBank: Sodium chloride (DB09153)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Saline solution treatment
Study: 31849123
Drug: l-carnitine (LC)
DrugBank: Levocarnitine (DB00583)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: l-carnitine (LC) 2 g for 8 weeks
Study: 29844808
Drug: Anti-reflux treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Anti-reflux treatment
Study: 20219962
Drug: Vitamin D(3)
DrugBank: Vitamin D (DB11094)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vitamin D(3) supplements (1200 IU/d)
Study: 17617938
Drug: Olive oils
Normalized name: Olive Oil
DrugBank: Olive oil (DB09567)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Olive oils rich in phenolic compounds
Study: 15613438
Drug: Oral calcium
Normalized name: Coral Calcium
DrugBank: Sodium citrate (DB09154)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral calcium administration (1 g calcium gluconate)
Study: 15613438
Drug: Peptone loading
Normalized name: peptones
Approvals — FDA: no, EMA: no, PMDA: no
Description: Peptone loading test (10 g protein hydrolyzed)
Study: 11849571
Drug: midazolam 0.5
Normalized name: midazolam 0.5 MG/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: midazolam 0.5 mg x kg(‐1) mixed with sodium citrate
Study: 11849571
Drug: midazolam 0.5
Normalized name: midazolam 0.5 MG/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: midazolam 0.5 mg x kg(‐1) mixed with Hawaiian fruit punch
Study: 8873835
Drug: Amoxicillin and
Normalized name: omeprazole, amoxicillin and rifabutin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Amoxicillin and clavulanic acid (1.2 g i.v. every 8 hours for 3-4 days, followed by 625 mg orally every 8 hours until labor)
Study: 1824374
Drug: Injection pen
Normalized name: Albiglutide 30 mg powder for solution for injection pen
Approvals — FDA: no, EMA: no, PMDA: no
Description: Injection pen system (Nordiject) for administration of B-hGH (Norditropin)
Study: 1824374
Drug: Syringe (4
Approvals — FDA: no, EMA: no, PMDA: no
Description: Syringe (4 IU/ml)
Study: 1824374
Drug: Injection pen
Normalized name: Albiglutide 30 mg powder for solution for injection pen
Approvals — FDA: no, EMA: no, PMDA: no
Description: Injection pen (Nordiject) (12 IU/ml)
Study: 30567952
Drug: 9-item Morisky
Normalized name: chloroxylenol
DrugBank: Chloroxylenol (DB11121)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 9-item Morisky Medication Adherence Scale (MMAS-9)
Study: 25166719
Drug: MK-5442 (2.5,
Approvals — FDA: no, EMA: no, PMDA: no
Description: MK-5442 (2.5, 5, 7.5, 10, or 15 mg)
Study: 25166719
Drug: MK-5442 (higher
Approvals — FDA: no, EMA: no, PMDA: no
Description: MK-5442 (higher doses)
Study: 18773914
Drug: Artificially sweetened
Normalized name: COLOR,ARTIFICIAL
Approvals — FDA: no, EMA: no, PMDA: no
Description: Artificially sweetened solutions (aspartame concentrations of 0, 0.01, 0.03, 0.08, and 0.28%)
Study: 17635944
Drug: Hypertonic saline
Normalized name: ENTSOL Hypertonic Saline Nasal Gel
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hypertonic saline infusion combined with thirsting for 17 hours
Study: 17635944
Drug: Hypotonic saline
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hypotonic saline infusion with iv desmopressin during free water intake
Study: 11079257
Drug: 80 mg/day
Approvals — FDA: no, EMA: no, PMDA: no
Description: 80 mg/day simvastatin and 2 mg folic acid/0.8 mg vitamin B12 daily (combination group)
Study: 11079257
Drug: 80 mg/day
Approvals — FDA: no, EMA: no, PMDA: no
Description: 80 mg/day simvastatin and placebo vitamins (simvastatin alone group)
Study: 11079257
Drug: 2 mg
Normalized name: iodine 2 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2 mg folic acid/0.8 mg vitamin B12 daily and placebo simvastatin (vitamins alone group)
Study: 9145970
Drug: Placebo/no treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo/no treatment